NPM1 and acute myeloid leukemia: These differences concerned the rates of secondary AML (56.9% vs. 32.4% in our study) and performance status > 1 (19% vs. 28%), white blood cell count (median, 3.3 vs. 5.2 giga per liter) and NPM1 mutations (12.2% vs. 29.6%).